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Respiratory syncytial virus (RSV) causes a significant public
health burden, and outbreaks among vulnerable patients in
hospital settings are of particular concern. We reviewed
published and unpublished literature from hospital settings to
assess: (i) nosocomial RSV transmission risk (attack rate) during
outbreaks, (ii) effectiveness of infection control measures. We
searched the following databases: MEDLINE, EMBASE,
CINAHL, Cochrane Library, together with key websites, journals
and grey literature, to end of 2012. Risk of bias was assessed
using the Cochrane risk of bias tool or Newcastle–Ottawa scale.
A narrative synthesis was conducted. Forty studies were included
(19 addressing research question one, 21 addressing question
two). RSV transmission risk varied by hospital setting; 6–56%
(median: 285%) in neonatal/paediatric settings (n = 14), 6–12%
(median: 7%) in adult haematology and transplant units
(n = 3), and 30–32% in other adult settings (n = 2). For
question two, most studies (n = 13) employed multi-component
interventions (e.g. cohort nursing, personal protective equipment
(PPE), isolation), and these were largely reported to be effective
in reducing nosocomial transmission. Four studies examined
staff PPE; eye protection appeared more effective than gowns
and masks. One study reported on RSV prophylaxis for patients
(RSV-Ig/palivizumab); there was no statistical evidence of
effectiveness although the sample size was small. Overall, risk of
bias for included studies tended to be high. We conclude that
RSV transmission risk varies widely during hospital outbreaks.
Although multi-component control strategies appear broadly
successful, further research is required to disaggregate the
effectiveness of individual components including the potential
role of palivizumab prophylaxis.
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What this paper adds
Respiratory syncytial virus (RSV) transmission risk is substantial
during outbreaks in hospital settings. Although multi-component
control strategies appear broadly successful in controlling nosoco-
mial RSV transmission, there is a lack of high-quality evidence and
further research is required to identify the effectiveness of discrete
measures including the role of palivizumab prophylaxis.
Introduction
Respiratory syncytial virus (RSV) causes a significant public
health burden; a systematic review and meta-analysis
estimated that globally the infection caused 338 million
(95% confidence interval [CI] 193–462 million) new
episodes of acute lower respiratory tract infections in
children <5 years old in 2005.1 It is an important cause of
severe respiratory disease in children, particularly those at
high risk of acute lower respiratory tract infections.2,3 RSV is
also common in adults, especially the elderly and other high-
risk groups such as those who are immunocompromised.4–6
RSV outbreaks among vulnerable hospitalised patients are of
particular concern as affected patients are more likely to
experience longer hospital stays, with increased risk of
morbidity and mortality.4,7,8 Numerous hospital outbreaks
have been reported in multiple age groups and settings
including neonatal intensive care, haematology, transplant
and oncology units.9–12
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RSV infection does not lead to long-term immunity.13
There is currently no specific treatment for RSV nor a
licensed vaccine,14 so controlling transmission is crucial. RSV
is transmitted via large nasopharyngeal secretion droplets
from infected individuals.15 These droplets enter via the
mucus membranes of the eyes, nose and mouth following
close contact, or self-inoculation after touching contami-
nated surfaces.15 Standard (routine) respiratory infection
control procedures such as isolation of cases, high standards
of hand hygiene, cohort nursing and use of personal
protective equipment (PPE) have been reported as effective,
to varying degrees, in the prevention and control of RSV
outbreaks in nosocomial settings.16–18 In more recent years,
immunoprophylaxis with the monoclonal antibody palivi-
zumab has been used during hospital RSV outbreaks for
patients at high risk of severe complications (e.g. preterm
infants).10–12,19,20 To our knowledge, the effectiveness of
RSV-specific infection control measures in the hospital
setting have not been subject to a high-quality systematic
review. A Cochrane review of physical interventions to
prevent respiratory virus infections was published in 2011,
but this was not specific to RSV or acute settings and did not
seek to identify studies reporting on the effectiveness of
palivizumab.21
We aimed to address the aforementioned gaps in the
evidence base through a systematic review of the published
and unpublished international literature. The specific
research questions were as follows: (i) What is the risk of
nosocomial RSV transmission where patients may have been
potentially exposed to the infection (epidemiologically
suspected or microbiologically confirmed) during an out-
break in a hospital ward or unit? and (ii) What is the
effectiveness of infection prevention and control measures to
minimise nosocomial transmission of RSV in the hospital
setting?
Methods
Protocol registration and study conduct
The review protocol was registered with the PROSPERO
International prospective register of systematic reviews,
registration number: CRD42013003835.22 It was conducted
following the general principles of the Cochrane Handbook
for Systematic Reviews of Interventions,23 and is reported
according to the requirements of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA).24
Search strategy
We searched the following databases using MeSH and free-
text terms: MEDLINE, EMBASE, CINAHL and the Cochrane
Library (CENTRAL). Bandolier and the Cochrane Library
(CSDR, DARE, NHS HTA databases) were searched for
evidence-based reviews, and NHS Evidence (NHS Clinical
Knowledge Summaries and the National Library of Guide-
lines) to identify guidelines containing relevant data. Two of
the most relevant journals (Influenza and Other Respiratory
Viruses and Eurosurveillance) were hand-searched. Addi-
tional searches were conducted via Google, the Health
Protection Agency website (now Public Health England
[PHE]), the World Health Organization and the US Centers
for Disease Control and Prevention. Experts in the field were
consulted. Grey literature was sought via the Web of Science,
NHS Evidence and OpenSIGLE. Reference lists of the most
relevant records (~100) were searched, and Web of Science
(Science Citation Index) and Google Scholar were used for
citation tracking. Unpublished epidemiological data were
sought from the PHE respiratory outbreaks database.
Our search strategy was designed to identify studies
providing data addressing either or both research questions.
The generic list of search terms is available in the protocol,22
and the full electronic search strategy for MEDLINE in
Appendix 1. Searches were executed in February/March 2013
and included publications from the inception of each
database to the end of 2012, in the English language.
Searches were limited to humans. No restriction was placed
on either the publication type (e.g. abstracts, unpublished
works etc. were eligible) or study design. Review papers were
not eligible for inclusion but were obtained for reference list
searching.
Study selection (inclusion and exclusion criteria)
Search records were imported into Endnote. After removal of
duplicates, records were assessed for eligibility using a three-
stage sifting process sequentially reviewing titles, abstracts
and full texts. Each record was independently assessed by two
reviewers with the involvement of a third reviewer to resolve
disagreements. To be eligible, studies had to address at least
one of the two research questions. Only studies conducted in
hospital settings were eligible. We were interested in clinically
suspected RSV or bronchiolitis, or microbiologically con-
firmed RSV, epidemiologically suspected to be nosocomial in
origin. We accepted any description of a nosocomial (rather
than community) transmission, according to the authors’
own definition, as eligible. No restriction was placed on
laboratory technique for identifying RSV.
To be eligible for inclusion for question one, studies had to
(i) provide data on the risk of nosocomial RSV transmission
to patients (attack rate), defined as follows: number of
nosocomial RSV or bronchiolitis cases/number of patients
potentially exposed to RSV in the ward or unit; and (ii) be
conducted during an outbreak in a hospital ward or unit,
defined as two or more cases of RSV infection linked
epidemiologically in time and place or microbiologically
confirmed. Studies providing data for a whole RSV season or
routine surveillance data were not eligible. Research question
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two was defined as follows: Population: patients, staff or
visitors at risk of RSV infection in the hospital setting;
Intervention: RSV infection control measures; Comparator:
infection control measures which differ from the interven-
tion, or no intervention; and Outcome: nosocomial RSV
transmission in the intervention versus comparator group.
For question two, studies had to (i) state one or more RSV
infection control interventions, (ii) utilise a comparator
group and (iii) provide data on nosocomial RSV transmis-
sion in the intervention versus comparator groups, with no
restriction placed on the type of data that were reported (e.g.
risks or rates, risk or rate ratios, the ratio of RSV cases that
were nosocomial). For question two, studies were not
restricted to those conducted in the context of a specific
outbreak (e.g. routine surveillance data comparing two RSV
seasons were eligible). Studies which assessed the use of
palivizumab to prevent RSV outbreaks were eligible for
inclusion. Assessing the effectiveness of season-long palivi-
zumab prophylaxis for individual high-risk patients or
severity of RSV infection was beyond the scope of this
systematic review.
Data extraction
Two reviewers independently extracted data using a pre-
defined template. Disagreements were resolved by discussion
or by a third reviewer. For research question one, we
extracted the following: country and year of outbreak,
hospital setting, study objective and nosocomial transmission
risk (attack rate, number of nosocomial cases, number of
patients at risk). For research question two, we extracted the
following: country and year of outbreak, study design,
hospital setting, infection control measures for intervention
and comparator groups, and information on effectiveness of
control measures.
Risk of bias assessments
We assessed risk of bias, by domain, for all studies providing
comparative data on the effectiveness of infection control
interventions (i.e. addressing research question two). Exper-
imental and prospective cohort studies were assessed using
the Cochrane risk of bias tool,23 and retrospective cohort
studies using the Newcastle–Ottawa scale.25 Abstracts, con-
ference posters or proceedings were not assessed formally due
to the limited information available.
Data synthesis
A narrative approach was used to synthesise the extracted
data and quality assessments according to the framework
described by the Economic and Social Research Council and
recommended by the University of York Centre for Reviews
and Dissemination.26 Due to weak study designs and
heterogeneity between studies, including the range of differ-
ent control measures applied with most studies implement-
ing multicomponent measures, it was not considered
appropriate to carry out a meta-analysis.
Results
Included studies
The searches returned 16 558 records, 6913 after removal of
duplicates, with an additional six studies obtained through
reference list scanning. Forty studies were eligible for
inclusion, 19 addressing research question one and 21
addressing research question two (none addressed both)
(Figure 1). One outbreak recorded in the database held by
the PHE Respiratory Diseases Department met the eligibility
criteria for research question two.
Risk of nosocomial RSV transmission
Table 1 summarises the 19 studies providing data on the risk
of nosocomial RSV transmission. Eight were from Europe,
six from the United States and five from elsewhere. Most
(n = 14) were in neonatal/paediatric units (13 of which were
neonatal units),19,20,27–38 three in adult units for haemato-
logical cancers and/or bone marrow/stem cell transplant
recipients (hereafter referred to as immunocompromised
adults),39–41 and two in other adult units (a psychiatric ward
and a continuing-care ward for the elderly).42,43 In all
outbreaks, either all or the majority of diagnosed RSV cases
were laboratory confirmed. The extent of case searching
varied. The number of persons at risk ranged from 9 to 60 in
neonatal/paediatric settings, 60–195 in adult units for
immunocompromised adults and 25–27 in other adult units.
RSV transmission risk varied by hospital setting: from 6% to
56% (median: 285%) in neonatal/paediatric settings, 6–12%
(median: 7%) in units housing immunocompromised adults
and 30–32% in other adult care settings. All studies utilised
at least some type of infection control measures (either in
place prior to the outbreak or implemented in response to
it). The outbreak reported in the PHE database was in an
adult haematology unit that included bone marrow trans-
plant recipients. There were 20 persons at risk and the RSV
transmission risk was 30%.
Effectiveness of control measures to prevent
transmission events
Table 2 summarises characteristics of the 21 studies address-
ing research question two. Four were from Europe, 15 from
the United States and two from Canada. There were 13
experimental or prospective cohort studies15,16,18,44–53 and
seven retrospective cohorts54–60 (one was an abstract only
and there was not enough information to identify the study
type).61 Most (n = 18) were conducted in neonatal/paedi-
atric settings,15,16,18,44–53,55–57,60,61 with three in units hous-
ing immunocompromised adults.54,58,59 All studies employed
laboratory confirmation of RSV diagnoses.
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Studies on the effectiveness of interventions to prevent
nosocomial RSV transmission to patients and staff are
summarised in Tables 3 and 4, respectively. We found no
eligible studies on interventions to prevent transmission to
visitors. A range of different outcome measures were
reported in eligible studies including the nosocomial trans-
mission risk before and after the intervention, the rate of
transmissions (e.g. per number of patient-days at risk) in the
intervention versus control group, and risk or rate ratios.
Risk of bias assessments
Cochrane risk of bias assessments were carried out for the 13
experimental or prospective cohort studies (Table 5). For
domains relating to selection and performance bias (random
sequence generation, allocation concealment, blinding of
participants and personnel), the risk of bias was deemed high
for all but one study in which the risk for the first two
domains was unclear50. No studies reported blinding of
participants and personnel (that would largely not have been
possible due to the nature of the interventions). Detection
bias (blinding of outcome assessors) was considered low risk
for all studies because RSV cases were laboratory confirmed.
None of the studies sufficiently adjusted for potential
confounding. An additional potential bias is the ascertain-
ment of community-acquired rather than nosocomial RSV
cases. Eleven of the 12 studies investigating the risk of RSV
transmission to patients provided a clear definition of a
nosocomial case, with most (n = 8) defining this as a case
occurring at least 5 days after hospital admission (some used
a higher cut-off).15,18,45–49,51 In studies assessing the risk of
All records
16,558
Duplicates removed
9645
Sift at title
6913
Sift at abstract
581
Reject at title
6332
Reject at abstract
300
Sift at full text
281
Include at full text
34
(Question 1:17
Question 2:17)
Reject at full text
247 in total*
Stage 1
No epidemiology or control 
information on nosocomial
RSV (112)
Not an original study (64)
Not a hospital cohort (13)
Could not obtain (1)
Outside time limit (1)
Duplicate (1)
Total excluded: 192
Stage 2
Question 1
Not an outbreak (49)
Lack of numerator and/or
denominator (23)
Total excluded: 72
Question 2
Lack of comparator (72)
Total excluded: 72
Reference tracking
6
(Question 1:2
Question 2:4)
Citation tracking
0
Include in review
40
(Question 1:19
Question 2:21)
Figure 1. Study selection flow chart. *Note: As we used a single search strategy for the two research questions, a first sift of full-text records was used to
exclude records that were clearly not eligible for inclusion in the review as a whole. Each of the remaining studies (n = 89 [281–192]) was then
independently assessed for eligibility for each of the two research questions.
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transmission to hospital staff, no such case definition would
be possible. The risk of attrition bias was unclear in most
studies, with only two studies44,50 providing relevant infor-
mation. The risk of reporting bias was unclear for all studies.
Of the seven retrospective cohort studies assessed on the
Newcastle–Ottawa scale25 (Table 6), most scored highly on
selection of the study groups with six studies54–58,60 awarded
three or more stars for this domain. However, all studies
received zero stars for ‘comparability’ as none adjusted for
confounders or utilised a study design that matched individ-
uals in the intervention and comparator groups. Although all
but one study provided a clear definition of a nosocomial RSV
case,59 ascertainment of the outcome was poor overall
(generally due to insufficient follow-up or inadequate report-
ing of this); six studies were awarded one star only for this
domain54–58,60 and one awarded zero stars.59
Multicomponent interventions (Table 3)
Most studies (n = 13) employed multicomponent infection
control strategies (two or more measures com-
bined).16,18,46,48,49,51–54,56,59–61 These comprised a wide range
of measures including the following: prompt RSV case-
finding among symptomatic patients; screening all patients
on admission; screening staff and/or visitors; isolation
policies and/or staff/patient cohorting; restriction of visitors
(e.g. no young children); and staff training and/or compliance
monitoring. Most studies made some use of personal
protective equipment (PPE) (e.g. gowns, gloves, masks,
goggles). Studies of multicomponent control measures
essentially used ‘standard infection control precautions’, that
is usual practice (either explicitly stated or assumed, see
Table 3), as the comparator group. For example, data for
previous RSV seasons prior to the introduction of the
intervention were frequently utilised. Nine of the 13 studies
presented evidence that nosocomial infections were signifi-
cantly lower when a multicomponent intervention was
implemented and provided supporting statistical data (e.g.
P-value or risk ratio with confidence inter-
vals).16,18,46,48,49,51,54,56,60 Three studies reported data that
were suggestive of a beneficial effect but did not present any
supporting statistics (such as a P-value).53,59,61 Relative risk
reductions in transmission were variable but tended to be
quite substantial and were in excess of 50% for the majority of
studies, where calculable. One study using a multicomponent
intervention also provided information on transmission to
staff, although the risk was actually somewhat higher during
the intervention than control period (56% versus 42%, no P-
value presented).51 However, Langley et al. 52 compared data
for nine different hospitals using different combinations of
intervention measures (all included isolation or cohorting)
and concluded that RSV transmission to patients was not
reduced by any type of isolation policy used, and there was no
beneficial effect of a gloving or masking policy.
T
a
b
le
1
.
(C
o
n
ti
n
u
ed
)
A
u
th
o
r,
p
u
b
li
ca
ti
o
n
y
e
a
r
C
o
u
n
tr
y
,
y
e
a
r
o
f
o
u
tb
re
a
k
H
o
sp
it
a
l
se
tt
in
g
S
tu
d
y
o
b
je
ct
iv
e
*
N
o
so
co
m
ia
l
ca
se
s/
p
a
ti
e
n
ts
a
t
ri
sk
(%
)
In
fe
ct
io
n
co
n
tr
o
l
m
e
a
su
re
s*
*
H
u
an
g
,
2
0
0
9
4
2
Ta
iw
an
,
2
0
0
5
A
d
u
lt
s
–
o
th
er
To
re
p
o
rt
o
n
ex
p
er
ie
n
ce
o
f
co
n
ta
in
in
g
an
R
SV
o
u
tb
re
ak
in
a
p
sy
ch
ia
tr
ic
w
ar
d
8
/2
5
(3
2
0)
M
as
ks
,
g
lo
ve
s,
g
o
w
n
s,
h
an
d
w
as
h
in
g
,
is
o
la
ti
o
n
cu
b
ic
le
s,
p
at
ie
n
t
in
fo
rm
at
io
n
an
d
tr
ai
n
in
g
,
ex
cl
u
si
o
n
o
f
st
af
f
w
it
h
ea
rl
y
o
n
se
t
sy
m
p
to
m
s,
te
st
in
g
M
an
d
al
,
1
9
8
5
4
3
U
K
,
1
9
8
2
–1
9
8
3
A
d
u
lt
s
–
o
th
er
D
es
cr
ib
es
an
o
u
tb
re
ak
o
f
R
SV
in
fe
ct
io
n
in
a
co
n
ti
n
u
in
g
-c
ar
e
el
d
er
ly
w
ar
d
8
/2
7
(2
9
6)
N
o
n
e
sp
ec
ifi
ed
R
SV
,
re
sp
ir
at
o
ry
sy
n
cy
ti
al
vi
ru
s;
N
IC
U
,
n
eo
n
at
al
in
te
n
si
ve
ca
re
u
n
it
;
U
R
TI
,
u
p
p
er
re
sp
ir
at
o
ry
tr
ac
t
in
fe
ct
io
n
.
*
O
b
je
ct
iv
es
ex
p
lic
it
ly
st
at
ed
b
y
th
e
st
u
d
y
au
th
o
r
b
eg
in
w
it
h
‘T
o
..
.’
.
*
*
M
o
st
o
f
th
es
e
m
ea
su
re
s
w
er
e
ap
p
lie
d
in
re
sp
o
n
se
to
th
e
o
u
tb
re
ak
(a
lt
h
o
u
g
h
so
m
e
m
ay
h
av
e
al
re
ad
y
b
ee
n
in
p
la
ce
p
ri
o
r)
.
French et al.
274 ª 2016 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Table 2. Studies assessing the effectiveness of nosocomial RSV infection prevention and control measures (research question two)
Author,
publication year
Country setting,
study year Hospital setting Study objective* Study design
Agah, 198744 USA, 1984–1985 Paediatric To assess RSV infection rates in staff exposed to
RSV, comparing those who wore goggles and
masks with those who did not
Experimental
Gala, 198645 USA, 1984 Neonatal/paediatric To evaluate an eye–nose goggle in reducing
nosocomial RSV infection in patients and staff
Experimental
Garcia, 199754 USA, 1992–1994 Adults – haematological
cancers and/or bone
marrow/stem cell
transplant recipients
To assess the effectiveness of a multifaceted
infection control strategy in limiting the
nosocomial RSV infection among patients
Retrospective cohort
Gardner, 197355 UK, 1970–1972 Paediatric To measure the extent and clinical importance of
viral cross-infection
Retrospective cohort
Hall, 198115 USA, 1979 Neonatal/paediatric To evaluate the efficacy of use of gowns and
masks on the rate of nosocomial RSV in infants
and staff
Experimental
Hall, 197851 USA, 1976 Paediatric To evaluate methods to control the spread of
RSV infection on an infants ward during a
community outbreak
Prospective cohort
Isaacs, 199116 UK, 1986–1989 Neonatal/paediatric To investigate whether cohorting infants and
handwashing will reduce the incidence of
nosocomial RSV
Prospective and
retrospective cohort
Karanfil, 199956 USA, 1989–1997 Paediatric To report on implementation of control measures
to prevent nosocomial RSV transmission
Retrospective cohort
Katz, 200957 USA, 1990–2008 Neonatal To compare nosocomial RSV infection rate in a
NICU before and after RSV prophylaxis
Retrospective cohort
Krasinski, 199046 USA, 1987–1988 Paediatric To determine the efficacy of assignment to
cohorts to reduce nosocomial RSV transmission
Prospective cohort
Langley, 199752 Canada, 1992–1994 Paediatric To determine nosocomial RSV transmission,
outcomes and infection control practices
Prospective cohort
Lavergne, 201158 Canada, 1999–2003 Adults – haematological
cancers and/or bone
marrow/stem cell
transplant recipients
To evaluate impact of an enhanced infection
control programme on incidence of nosocomial-
acquired RSV and its consequences
Retrospective cohort
Leclair, 198747 USA, 1982-1985 Neonatal/paediatric To investigate the efficacy of a vigorous infection
control effort in reducing nosocomial RSV
transmission
Prospective cohort
Macartney, 200048 USA, 1988–1996 Neonatal/paediatric To determine the cost-effectiveness and cost–
benefit of an infection control programme to
reduce nosocomial RSV transmission
Prospective cohort
Madge, 199218 UK, 1989-1992 Neonatal/paediatric To define the most effective infection control
procedure for the prevention of nosocomial
infection on wards with limited isolation
facilities
Prospective cohort
Page, 200761 USA, 1996–2002 Paediatric Reports on a comprehensive RSV isolation policy
to prevent nosocomial RSV transmission
N/A (abstract only)
Raad, 199759 USA, 1994–1996 Adults – haematological
cancers and/or bone
marrow/stem cell
transplant recipients
Reports on a multifaceted control strategy to
reduce nosocomial RSV transmission
Retrospective cohort
Hall, 197753 USA, NS Neonatal/paediatric To identify shedding patterns of RSV, spread of
RSV infection within families (in a community
setting) and nosocomial spread of RSV
Prospective cohort
Murphy, 198150 USA, 1979 Paediatric To examine the effects of various control
methods on the acquisition of symptomatic
respiratory infections among medical staff
caring for infants with respiratory disease
Prospective cohort
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Staff personal protective equipment (Tables 3 and 4)
Five studies examined the use of staff PPE in addition to
standard precautions, all conducted in neonatal/paediatric
settings.15,44,45,47,50 Two examined the effect on RSV trans-
mission to both staff and patients,15,45 two examined the risk
of transmission to staff only,44,50 and the remaining study
looked only at transmission to patients.47 Of the three studies
providing data on patients (Table 3),15,45,47 two reported PPE
to be effective. Gala et al. 45 implemented an eye–nose goggle
for all staff and reported a transmission risk of 43% in the
control and 6% in the intervention periods (v2: P = 004).
Leclair et al. 47 examined the effect of monitoring staff
compliance with PPE where it was hospital policy for staff to
wear gloves and gowns when in direct contact with RSV
patients. This study reported a lower risk of nosocomial
transmission during the period in which intensive staff
compliance monitoring was implemented compared to the
pre-intervention period (relative risk adjusted for intensity of
exposure: 29 [95% CI: 15–57]). However, authors of the
third study reported that they found no significant difference
in the rate of nosocomial RSV transmission to patients when
gowns and masks were used (32%) compared with standard
procedures alone (41%) (no P-value provided).15 Of the four
studies examining the effectiveness of measures to prevent
RSV transmission to staff (Table 4),15,44,45,50 two found
evidence of effectiveness, both of which utilised goggles (one
used goggles andmasks44 and the other an eye–nose goggle45).
In the two studies reporting no statistically significant benefit,
neither used goggles (just gowns and masks), although it
should be noted that in both these studies the risk of
transmission (based on the point estimates) was still lower in
the intervention than the comparator groups.15,50
RSV prophylaxis (Table 3)
Only one eligible study, in a neonatal unit, reported on post-
admission RSV prophylaxis for patients.57 Standard infection
control procedures in the unit involved placing infected
infants in single rooms or cohorting them and using droplet/
contact isolation measures. The authors reported no significant
difference in nosocomial RSV infection rates during the
RSV seasons in which RSV prophylaxis (RSV-Ig or
palivizumab) was given monthly to all high-risk infants in
the unit in addition to standard infection control proce-
dures: rate ratio for period 1 (no prophylaxis) versus period
2 (RSV-Ig): 067 (95% CI: 003–14, P = 076); and for
period 1 (no prophylaxis) versus period 3 (palivizumab):
33 (95% CI: 016–68, P = 037). However, the point
estimates indicated a potential beneficial effect of palivizu-
mab, and it should be noted that the power to detect a
statistically significant difference was likely low due to the
very small number of cases.57
Other interventions (Table 3)
One study compared the RSV transmission risk in wards
comprising mainly of individual cubicles with the risk in
open wards combined with a smaller number of cubicles.
Although the numbers of nosocomial infections were too
small to make statistical comparisons, the rate of nosocomial
RSV infections was somewhat lower in wards composed
largely of individual cubicles (71 versus 42 infections per
million susceptible days per infective day).55 Meanwhile, in a
haematology–oncology ward, isolating all patients hospi-
talised during an RSV season resulted in statistically signif-
icantly lower RSV transmission than the previous policy of
only isolating patients with severe neutropenia or symptoms
of upper and/or lower respiratory tract infection (relative risk
in intervention versus control period: 009 [95% CI: 002–
038]).58
Discussion
Key findings
To our knowledge, this is the first systematic review of
nosocomial RSV transmission risk and the effectiveness of
infection control measures to prevent transmission in
acute care settings. Nosocomial RSV transmission risk is
Table 2. (Continued)
Author,
publication year
Country setting,
study year Hospital setting Study objective* Study design
Simon, 200649 Germany, 1999–2002 Paediatric To assess the local epidemiology of nosocomial
RSV infections and evaluate the global efficacy
of a complex intervention programme
Prospective cohort
Snydman, 198860 USA, 1984–1986 Neonatal To investigate the impact of additional infection
control methods for nosocomial RSV
Retrospective cohort
RSV, respiratory syncytial virus; NICU, neonatal intensive care unit; PICU, paediatric intensive care unit; LRTI, lower respiratory tract infection; URTI,
upper respiratory tract infection; NS, not specified.
*Objectives explicitly stated by the study author begin with ‘To. . .’.
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substantial during outbreaks in hospital settings, with
notable variations across outbreaks and settings. Most studies
in this review were conducted in neonatal/paediatric settings
where the median transmission risk was 285%. While all
studies utilised at least some infection control measures, the
identified transmission risks are concerning and highlight a
serious challenge. This review highlights the lack of high-
quality studies describing the effectiveness of infection
control measures to prevent nosocomial RSV.
The majority of studies implemented multicomponent
interventions, as appropriate for infection control in hospital
settings and in accordance with, for example, UK guidelines.62
The evidence presented here broadly supports the use of
multicomponent measures which tended to achieve relative
reductions in transmission risk of over 50%. However, within
this context, it was not possible to assess the effectiveness of
individual components of control measures, either within
individual studies or at the review level. Some components
may be more effective than others, and identifying these could
result in more efficient use of resources and further reduc-
tions in transmission risk. Furthermore, the potential harms
of interventions, particularly those without measurable
benefit, should not be overlooked.
Personal protective equipment worn by staff may poten-
tially prevent transmission from patients to staff and vice
versa. Two studies in which staff eye protection was used
(eye–nose goggle45 or goggles plus masks44) found this to be
effective in preventing transmission to staff (the first also
reported a reduction in transmission to patients, but this was
not investigated in the second study). This finding is
consistent with RSV transmission generally occurring
through the eye or nose.63 Evidence for the effectiveness of
gowns and masks was lacking in two studies15,50 although a
further study did find high (versus lower) compliance with
gloves and gowns to be effective at reducing nosocomial RSV
transmission.47 In relation to the transmission of RSV to
Table 5. Cochrane risk of bias assessments for experimental and prospective cohort studies
Random
sequence
generation
Allocation
concealment
(selection
bias)
Blinding of
participants
and personnel
(performance
bias)
Blinding of
outcome
assessment
(detection
bias)
Incomplete
outcome
data
(attrition
bias)
Selective
reporting
(reporting
bias)
Other
sources of
bias 1
(other bias –
case definition)
Other sources
of bias 2
(other bias –
confounding)
Agah, 198744      ?  
Gala, 198645*    + ? ? + 
Hall, 198115*    + ? ? + 
Hall, 197851    + ? ? + 
Isaacs, 199116    + ? ? ? 
Krasinski, 199046    + ? ? + 
Langley, 199752    + ? ? + 
Leclair, 198747    + ? ? + 
Macartney,
200048
   + ? ? + 
Madge, 199218    + ? ? + 
Hall, 197753    + ? ? ? 
Murphy, 198150 ? ?  + + ?  
Simon, 200649    + ? ? + 
Key: : high risk of bias; +: low risk of bias; ?: unclear risk of bias.
*The studies by Gala et al. (1981) and Hall et al. (1981) both investigated RSV transmission to staff as well as patients. A ‘low’ rating has been
assigned for the ‘other bias – case definition’ domain based on the nosocomial case definition used for RSV cases occurring among patients, but it
should be noted that no such definition was applied to RSV cases occurring among staff.
Table 6. Newcastle–Ottawa ratings for retrospective cohort studies
Selection
stars
Comparability
stars
Outcome
stars
Garcia, 199754 * * * *
Gardner, 197355 * * * * *
Karanfil, 199956 * * * *
Katz, 200957 * * * *
Lavergne, 201158 * * * *
Raad, 199759 * *
Snydman, 198860 * * * *
Note: A maximum of four stars can be awarded for ‘Selection’, two
stars for ‘Comparability’ and three stars for ‘Outcome’. Where a box is
blank, this is because zero stars were awarded.
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staff, there were four eligible studies, all of which investigated
PPE as the intervention of interest. Of course, PPE is not the
only potentially effective precaution; for example, staff/
patient cohorting may also prevent transmission. Meanwhile,
strict isolation precautions appeared to be effective in the two
studies investigating this specifically,55,58 but the resource
implications of such policies (e.g. isolating all patients
hospitalised during the RSV season in a given unit)58 may
make them impractical to implement in many settings,
especially in low- and middle-income countries.
Although palivizumab is considered to be effective in
preventing RSV-related hospitalisation in high-risk children
(outside the scope of this review),64–66 we uncovered limited
evidence regarding its use in hospitalised patients to prevent
nosocomial RSV transmission. Our literature search returned
12 studies; however, only one of these met the review
eligibility criteria for research question two.57 Of the 11 other
studies (all of which lacked a comparator group), all but one
were conducted in NICUs. Eight reported no further RSV
cases following palivizumab prophylaxis,10,11,28,32,33,38,67,68
and one reported no further cases after day 14 of the
outbreak having instigated control measures on day nine.30
Two reported the occurrence of two further cases after
palivizumab administration.19,69 Meanwhile, Silva et al. 20
documented the occurrence of 10 RSV cases following
prophylaxis administration to all patients, although the
authors noted these infants may have already been in the
RSV incubation period when palivizumab was administered.
These additional data underscore the need for high-quality
studies in hospital settings to generate robust evidence to
support clinicians and public health policy, particularly
bearing in mind the high cost of palivizumab.70
Limitations
RSV is a significant problem across low- and middle-income
countries.1 However, the majority of evidence on the risk of
RSV transmission, and all evidence on interventions to
interrupt transmission in this review came from the United
States and Europe. Extrapolation of our findings to low- and
middle-income countries where resources are lacking may be
difficult.
To calculate the nosocomial RSV attack rate, the denom-
inator was the number of persons at risk of infection as few
studies provided the person-time at risk. Although this is a
crude denominator, it allowed for comparisons across
studies. The definition of a nosocomial transmission event
varied between studies and we accepted any description of a
nosocomial event, as defined by the author, as eligible. This
may have resulted in some misclassification between noso-
comial and community-acquired RSV. Additionally, patients
infected with RSV in hospital who did not develop symptoms
until after discharge, were likely not identified by the studies,
especially if symptoms were mild and they did not require
re-admittance to hospital (most studies did not report
following up patients after discharge). Also, we cannot discount
the potential for under-reporting of nosocomial RSV outbreaks
leading to reduced external validity of our findings.
We did not identify any randomised controlled trials on
the effectiveness of RSV infection control measures. Obser-
vational studies are subject to inherent biases and further-
more, assessing the risk of bias in non-randomised studies is
difficult in itself.23 On the whole, available studies were
assessed as having a relatively high risk of bias. A number of
the studies utilised comparator data from a different time
period (such as prior RSV seasons) and thus are subject to
confounding due to differences between the population
groups and levels of exposure to RSV. Studies typically did
not clearly report the population characteristics of the two
groups or control any potential differences, thus making
comparisons difficult and potentially subject to bias. Few
studies monitored compliance with infection control mea-
sures, which has been reported to frequently be suboptimal.71
High levels of compliance may be necessary for certain
infection control measures to be effective. Finally, it should
be noted that a number of the studies were poorly reported
with a lack of clarity, for example, with regard to the study
population and type/timing of interventions. Reporting of
future studies in line with the ORION (Outbreak Reports
and Intervention Studies Of Nosocomial infection) statement
would improve their usefulness.72
Conclusion
RSV transmission risk varies widely during hospital out-
breaks. Although there is a lack of high-quality evidence,
multicomponent control strategies appear broadly successful,
while PPE interventions using eye protection appear more
effective than those using gowns and masks. Further research
is required, especially in low- and middle-income countries,
to identify the most effective and cost-effective individual
control measures including the potential role of palivizumab
prophylaxis during nosocomial outbreaks.
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Appendix 1 MEDLINE search strategy
1. exp Hospitals/
2. exp Hospitalization/
3. exp Hospital Units/
4. exp Intensive Care Units/
5. exp Intensive Care Units, Neonatal/
6. exp Intensive Care Units, Pediatric/
7. exp Respiratory Care Units/
8. hospital*.mp.
9. ward.mp.
10. unit.mp.
11. icu.mp.
12. nicu.mp.
13. hdu.mp.
14. picu.mp.
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
or 13 or 14
16. exp Infection Control/
17. exp Communicable Disease Control/
18. exp Infection Control Practitioners/
19. exp Quarantine/
20. exp Patient Isolation/
21. exp Patient Isolators/
22. exp Hygiene/
23. exp Anti-Infective Agents, Local/
24. exp Disinfectants/
25. exp Protective Clothing/
26. exp Protective Devices/
27. exp Respiratory Protective Devices/
28. exp Gloves, Protective/
29. exp Masks/
30. exp Eye Protective Devices/
31. exp Ribavirin/
32. exp Antiviral Agents/
33. exp Social Distance/
34. exp Hypochlorous Acid/
35. exp Detergents/
36. exp Decontamination/
37. exp Disinfection/
38. exp Sterilization/
39. exp Hand Disinfection/
40. exp Soaps/
41. exp Filtration/
42. exp Inhalation Exposure/
43. prevention.mp.
44. control.mp.
45. communicable disease control.mp.
46. antisep*.mp.
47. isolat*.mp.
48. quarantin*.mp.
49. barrier nursing.mp.
50. hygiene.mp.
51. anti-infective.mp.
52. disinfectant.mp.
53. gown.mp.
54. gloves.mp.
55. mask.mp.
56. goggles.mp.
57. eye protection.mp.
58. cohort nursing.mp.
59. ribavirin.mp.
60. palivizumab.mp.
61. antiviral.mp.
62. synagis.mp.
63. copegus.mp.
64. rebetol.mp.
65. virazole.mp.
66. airborne precautions.mp.
67. social distance.mp.
68. droplet precautions.mp.
69. respiratory hygiene.mp.
70. cough measures.mp.
71. personal protective devices.mp.
72. personal protective equipment.mp.
73. ppe.mp.
74. clean*.mp.
75. hypochlorite.mp.
76. detergent*.mp.
77. decontamin*.mp.
78. alcohol rub.mp.
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79. handwashing.mp.
80. hand-rub.mp.
81. particulate filter.mp.
82. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or
35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44
or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or
54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63
or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or
73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81
83. exp Respiratory Syncytial Virus, Human/
84. exp Bronchiolitis, Viral/
85. respiratory syncytial virus.mp.
86. rsv.mp.
87. bronchiolitis.mp.
88. 83 or 84 or 85 or 86 or 87
89. 15 and 88
90. 15 and 82 and 88
91. limit 89 to (English language and humans and
year = ‘1860–2012’)
92. limit 90 to (English language and humans and
year = ‘1860–2012’)
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